Viking Therapeutics

205 articles about Viking Therapeutics

• 

  Viking Enters Weight-Loss Arena with Promising Phase I Data

  3/29/2023

  Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.

• Viking Therapeutics Announces Proposed Public Offering of Common Stock - March 29, 2023

  3/29/2023

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

• Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735

  3/28/2023

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced positive results from the company's Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735.

• Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

  3/28/2023

  Viking Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.

• Viking Therapeutics to Participate at Upcoming Investor Conferences - March 7, 2023

  3/7/2023

  Viking Therapeutics, Inc. today announced that the company will participate at two upcoming investor conferences. 

• Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

  2/8/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Present at SVB Securities Global Biopharma Conference

  2/7/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the SVB Securities Global Biopharma Conference.

• Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023

  2/1/2023

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will release financial results for the fourth quarter and year-end 2022, after the market close on Wednesday, February 8, 2023.

• Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

  1/9/2023

  Viking Therapeutics, Inc. today announced the completion of patient enrollment in its Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

• Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints

  1/2/2023

  Ascletis Pharma Inc. was recently informed that on December 29, 2022, Viking Therapeutics, Inc., a pharmaceutical company in the United States, filed certain complaints against Ascletis, its founder Dr. Jinzi Jason WU and certain subsidiaries of Ascletis in connection with the drug candidates ASC41 and ASC43F.

• Viking Therapeutics to Present at Stifel 2022 Healthcare Conference

  11/8/2022

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel 2022 Healthcare Conference.

• Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022

  10/19/2022

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2022, after the market close on Wednesday, October 26, 2022.

• Viking Therapeutics to Participate at Upcoming September 2022 Investor Conferences

  9/6/2022

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate at two upcoming investor conferences.

• Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022

  8/2/2022

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the BTIG Biotechnology Conference 2022. 

• Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  7/27/2022

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), today announced its financial results for the second quarter and six months ended June 30, 2022, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022

  7/20/2022

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), announced today that the company will release financial results for the second quarter 2022, after the market close on Wednesday, July 27, 2022.

• Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

  7/19/2022

  Viking Therapeutics, Inc. today announced that the FDA has lifted the clinical hold placed on the clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD).

• Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022

  7/6/2022

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the William Blair Biotech Focus Conference 2022.

• Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference

  5/16/2022

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C. Wainwright Global Investment Conference.

• Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

  4/27/2022

  Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2022, and provided an update on its clinical pipeline and other corporate developments.